Division of Hematology, Oncology and Transplantation

submenu
  • Committed to providing the highest quality care based on cutting edge research to patients with cancer or non-malignant hematologic diseases such as sickle cell disease

  • Dedicated to advancing research on the biological underpinnings of cancer, stem cell biology, sickle cell anemia, endothelial cell biology, and tumor immunology

  • Over 50 full-time academic investigators involved in interdisciplinary research and patient care are devoted to training the next generation of academic leaders

Division Chief

Dr. Weisdorf, Division Director for HOT

Daniel Weisdorf, MD

Announcements

Gregory Vercellotti, MD, FACP, was appointed to a two-year term on the Sickle Cell Disease Advisory Committee of the National Heart, Lung, and Blood Institute. As a member of the Committee, Dr. Vercellotti will provide scientific guidance on matters relating to the cause, prevention, diagnosis, and treatment of sickle cell disease and help to shape federal policy and guidelines aimed at improving the lives of patients with this genetic blood disorder. The Committee reviews research, research training programs, and cooperative agreements that show promise in helping to enhance the prevention or treatment of sickle cell disease. During his 37 years as a researcher and clinician, Dr. Vercellotti has focused on the mechanisms by which hemolysis, oxidative stress, and inflammation drive the vascular pathobiology underlying sickle cell disease. Supported by multiple research grants, Dr. Vercellotti's laboratory is conducting research to find new ways to treat sickle cell disease and test new therapies to prevent the blood vessel blockage that causes the devastating organ damage and pain in patients with the disease. Please join us in congratulating Dr. Vercellotti on his appointment to the prestigious Sickle Cell Disease Advisory Committee. March 2017

John Belcher, PhD, and Greg Vercellotti, MD, received a $316,060 grant from CSL Bering, a global leader in the plasma protein biotherapeutics industry. With the support of this grant, Drs. Belcher and Vercellotti will continue to investigate the efficacy of purified human haptoglobin and hemopexin in a murine model of sickle cell disease. March 2017